Aspira Pathlab & Diagnostics Schedules Board Meeting To Consider Fund Raise

Board meeting on August 12, 2026 will consider unaudited standalone Q1 FY2027 results and evaluate fundraising through equity shares, warrants, preferential issue, private placement, rights issue or other permitted methods, subject to approvals.